Carboplatin and Pemetrexed: What to Expect

Pemetrexed is an antifolate. That means it blocks enzymes that need folate, the B vitamin your cells use to build DNA. Cancer cells divide fast, so they feel the block first. Carboplatin is a platinum drug. It binds to DNA and creates cross-links that the cell cannot repair. The two drugs damage cancer cells in different ways, which is why they are paired.

The pairing is used most often in nonsquamous non-small cell lung cancer (NSCLC). Nonsquamous means the tumor cells are adenocarcinoma or large cell, not squamous. That distinction matters. Pemetrexed is not approved for squamous NSCLC, because trials showed it worked less well there. Pemetrexed is also used with cisplatin for pleural mesothelioma.

This step surprises people. The pemetrexed label tells your team to start folic acid 400 to 1,000 micrograms by mouth once a day, beginning 7 days before the first dose. You keep taking it until 21 days after the last dose. You also get a vitamin B12 shot into a muscle 1 week before the first dose, then every 3 cycles.

These are not general health vitamins. They cut the rate of low blood counts and mouth sores. The label is blunt on one point: do not swap oral B12 for the shot. Later B12 shots can be given on the same day as treatment.

You also take dexamethasone, a steroid, 4 milligrams by mouth twice a day for 3 days in a row, starting the day before each infusion. That schedule is there to prevent a skin rash.

Those steroid tablets are yours to take at home, and starting them the day before is the part people most often miss. Follow the schedule and the amount on your own prescription rather than this page, and tell the unit if you have not been able to take them, because it changes what happens on the day.

One cycle is 21 days. Day 1 is infusion day. Days 2 through 21 are recovery. Blood work happens before each cycle, and often once in between.

On day 1, the order matters. Pemetrexed goes in first, over 10 minutes. Carboplatin follows. The adult dose of pemetrexed is worked out from your body surface area. Carboplatin is not dosed by body size. It is dosed to a target blood exposure called AUC, or area under the curve. The Calvert formula sets it:

Total dose in milligrams = target AUC x (GFR + 25)

GFR is your kidney filtration rate. Your team picks a target exposure for the lungs, then the pharmacy converts it into millilitres in a bag. Note what this means in practice: two people of the same height and weight can get very different carboplatin doses, because their kidneys differ.

Chair time on day 1 usually runs 2 to 4 hours once you add anti-nausea drugs and flushes. If pembrolizumab (Keytruda) is part of your plan, it goes in before the pemetrexed.

Pemetrexed leaves the body through the kidneys. The label sets a hard floor: do not give it when creatinine clearance is under 45 mL/min. Creatinine clearance is a kidney number your team estimates with the Cockcroft-Gault equation, using your creatinine level, age, weight, and sex. There is no recommended dose below 45 mL/min.

So expect a creatinine check before every cycle. If it drifts up, treatment gets held until clearance is back to 45 mL/min or higher.

One over-the-counter drug matters here. Ibuprofen raised pemetrexed toxicity in people with mild to moderate kidney impairment. If your clearance is between 45 and 79 mL/min, ask before taking ibuprofen (Advil, Motrin). Acetaminophen is usually the safer choice for aches, but confirm it with your team.

Blood counts drive dose changes, and the rules are written down. Treatment is not given when the absolute neutrophil count (ANC, the infection-fighting white cells) is under 1,500 per cubic millimeter or platelets are under 100,000.

After a cycle, the next dose drops based on the worst count reached:

• ANC under 500, or platelets under 50,000 without bleeding: next dose is 75 percent of the last one.
• Platelets under 50,000 with bleeding: next dose is 50 percent.
• Severe drop again after two reductions: stop the drug.

Non-blood problems have their own rules. Grade 3 or 4 mouth sores cut the dose to 50 percent. Diarrhea bad enough to need hospital care cuts it to 75 percent. Grade 3 or 4 nerve damage means stopping pemetrexed for good.

In KEYNOTE-189, the trial that paired this chemo with pembrolizumab, the effects seen in at least 20 percent of people were fatigue, nausea, constipation, diarrhea, low appetite, rash, vomiting, cough, shortness of breath, and fever. Treatment was interrupted in 49 percent of people at some point. The most common reasons were low neutrophils (12 percent) and anemia (7 percent).

Carboplatin adds its own list. Its label reports hypersensitivity in about 2 percent of people, with rash, hives, itching, and rarely wheezing or low blood pressure. Risk of an allergic reaction rises with repeated platinum exposure, so a reaction in cycle 6 is more likely than one in cycle 1. Anemia from carboplatin can build up over cycles and may need a transfusion.

Two rarer pemetrexed warnings are worth knowing by name. Bullous skin toxicity means blistering or peeling skin, and it is a reason to stop the drug for good. Interstitial pneumonitis is inflammation in the lung tissue itself, and new or worsening breathlessness means treatment is held until it is sorted out.

Fever during chemotherapy is an emergency, not something to watch overnight. Call your oncology team at once, at any hour, or go to an emergency department if you cannot reach them.

• Fever. The numbers here differ by source, so know which one your team uses. NCI's patient page on infection says to call for 100.4 F (38 C) or higher. The clinical definition of neutropenic fever, used in emergency rooms, is one oral reading of 101 F (38.3 C) or higher, or 100.4 F (38 C) held for at least an hour, in someone whose ANC is under 1,500. The safe move is to call at 100.4 F and let them decide.
• Shaking chills, even with a normal temperature.
• New or worse shortness of breath.
• Bleeding that will not stop, black stools, or blood in urine.

• A new cough that will not settle.
• Skin blisters, peeling, or sores in the mouth, nose, or genital area.
• You are passing much less urine than usual.
• Numbness or tingling that is spreading in hands or feet.

Ask what carboplatin AUC target your team picked and what your GFR estimate was. Ask how many cycles of the platinum are planned; four is common before switching to maintenance. Ask whether pemetrexed will continue alone after the carboplatin stops. Ask who to call at 2 a.m., and get the number written down before you leave.

Chemotherapy, How Chemotherapy Is Given, Low White Blood Cells During Chemotherapy, Fever During Chemo, and Maintenance Immunotherapy After Lung Cancer Treatment.

• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae77f00f-d43b-4b75-afd5-a2a9cb7138da
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48aa7ef3-9f44-2a08-e054-00144ff88e88
• https://medlineplus.gov/druginfo/meds/a607043.html
• https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq
• https://www.cancer.gov/about-cancer/treatment/side-effects/infection
• https://www.ncbi.nlm.nih.gov/books/NBK541102/